Veraxa Biotech AG - Post de-SPAC SEC filings VRXAW

Veraxa Biotech AG - Post de-SPAC has 56 filings in SEC EDGAR's recent list, going back to Jul 31, 2025. Its latest annual report, Form 20-F, was filed on Jun 16, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 15, 2026. The company's fiscal year ends on December 31.

Veraxa Biotech AG - Post de-SPAC SEC filings
Form Description Filed Period
6-K Current report (foreign issuer) Oct 15, 2026 Oct 15, 2026
6-K Current report (foreign issuer) Sep 4, 2026 Sep 4, 2026
6-K Current report (foreign issuer) Aug 24, 2026 Aug 24, 2026
6-K Current report (foreign issuer) Jul 31, 2026 Jul 31, 2026
6-K Current report (foreign issuer) Jul 27, 2026 Jul 27, 2026
6-K Current report (foreign issuer) Jul 27, 2026 Jul 27, 2026
6-K Current report (foreign issuer) Jun 18, 2026 Jun 18, 2026
6-K Current report (foreign issuer) Jun 11, 2026 Jun 10, 2026

Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
VRXA (Nasdaq), VRXAW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Switzerland
Headquarters
Zurich
SEC filer status
, Emerging growth company
SEC CIK
2079109
Former names
Veraxa Biotech Holding AG (until Aug 13, 2026)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.